Ceftolozane/tazobactam: place in therapy.

Ceftolozane/tazobactam: place in therapy.
Expert Rev Anti Infect Ther. 2018 Mar 01;:
Authors: Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, Pea F, Rossolini G, Tumbarello M, Viale P, Viscoli C, ISGRI-SITA (Italian Study Group on Resistant Infection of the Società Italiana Terapia Antinfettiva)
Abstract
INTRODUCTION: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative...

Source: Expert Review of Anti-Infective Therapy - March 3, 2018 Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research